Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GPC3-targeted autologous CAR T-cell study in advanced hepatocellular carcinoma
ChiCTR1800015855Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jun 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GPC3-targeted autologous CAR T cells in hepatocellular carcinoma (HCC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Safety and tolerability, Cell pharmacokinetics and 1 more. Started Jun 2018; status: recruiting.
02
Drugs
GPC3-targeted autologous CAR T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR1800015855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015855.